These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24709267)

  • 1. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.
    Jeremiah K; Denti P; Chigutsa E; Faurholt-Jepsen D; PrayGod G; Range N; Castel S; Wiesner L; Hagen CM; Christiansen M; Changalucha J; McIlleron H; Friis H; Andersen AB
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3468-74. PubMed ID: 24709267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.
    Denti P; Martinson N; Cohn S; Mashabela F; Hoffmann J; Msandiwa R; Castel S; Wiesner L; Chaisson RE; McIlleron H; Dooley KE
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1234-41. PubMed ID: 26643345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
    Chirehwa MT; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; McIlleron H; Denti P
    Antimicrob Agents Chemother; 2016 Jan; 60(1):487-94. PubMed ID: 26552972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
    van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot randomized trial of nutritional supplementation in patients with tuberculosis and HIV-tuberculosis coinfection receiving directly observed short-course chemotherapy for tuberculosis.
    Sudarsanam TD; John J; Kang G; Mahendri V; Gerrior J; Franciosa M; Gopal S; John KR; Wanke CA; Muliyil J
    Trop Med Int Health; 2011 Jun; 16(6):699-706. PubMed ID: 21418447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.
    te Brake LH; Ruslami R; Later-Nijland H; Mooren F; Teulen M; Apriani L; Koenderink JB; Russel FG; Burger DM; Alisjahbana B; Wieringa F; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2015; 59(6):3233-9. PubMed ID: 25801554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    Sekaggya-Wiltshire C; von Braun A; Scherrer AU; Manabe YC; Buzibye A; Muller D; Ledergerber B; Gutteck U; Corti N; Kambugu A; Byakika-Kibwika P; Lamorde M; Castelnuovo B; Fehr J; Kamya MR
    J Antimicrob Chemother; 2017 Apr; 72(4):1172-1177. PubMed ID: 28108678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low rifampicin concentrations in tuberculosis patients with HIV infection.
    Gengiah TN; Botha JH; Soowamber D; Naidoo K; Abdool Karim SS
    J Infect Dev Ctries; 2014 Aug; 8(8):987-93. PubMed ID: 25116663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection.
    Ahmed R; Cooper R; Foisy M; Der E; Kunimoto D
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):273-6. PubMed ID: 22875581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
    Bwakura Dangarembizi M; Samson P; Capparelli EV; Moore CB; Jean-Philippe P; Spector SA; Chakhtoura N; Benns A; Zimmer B; Purdue L; Jackson C; Wallis C; Libous JL; Chadwick EG;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):473-480. PubMed ID: 31241542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.
    Kwara A; Enimil A; Gillani FS; Yang H; Sarfo AM; Dompreh A; Ortsin A; Osei-Tutu L; Kwarteng Owusu S; Wiesner L; Norman J; Kurpewski J; Peloquin CA; Ansong D; Antwi S
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):356-365. PubMed ID: 26407268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
    J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.